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Objectives: A recent report (J Clin Invest 1993;92:831-9) found no effect of 
glutamate plus aspartate on metabolic pathways in the heart, but the 
experimental conditions did not model clinical cardioplegia. The purpose of 
this study was to determine the effects of glutamate and aspartate on 
metabolic pathways feeding the citric acid cycle during cardioplegic arrest 
in the presence of physiologic substrates. Methods: Isolated rat hearts were 
supplied with fatty acids, lactate, pyruvate, glucose, and acetoacetate in 
physiologic oncentrations. These substrates were enriched with 13C, which 
allowed a complete analysis of substrate oxidation by 13C-nuclear magnetic 
resonance spectroscopy in one experiment. Three groups of hearts were 
studied: arrest with potassium cardioplegic solution, arrest with cardiople- 
gic solution supplemented with glutamate and aspartate (both in concen- 
trations of 13 mmol/L), and a control group without cardioplegic arrest. 
Results: In potassium-arrested hearts, the contributions of fatty acids and 
lactate to acetyl coenzyme A were reduced, and acetoacetate was the 
preferred substrate for oxidation in the citric acid cycle. The addition of 
aspartate and glutamate in the presence of cardioplegic arrest did not further 
alter patterns of substrate utilization substantially, although acetoacetate use 
was somewhat lower than with simple cardioplegic arrest. When [U-13C]glu - 
tamate (13 mmol/L) and [U-13C]aspartate (13 mmol/L) were supplied as the 
only compounds labeled with 13C, little enrichment in citric acid cycle 
intermediates could be detected. Conclusions: Glutamate and aspartate when 
added to potassium cardioplegic solutions have relatively minor effects on 
citric acid cycle metabolism. (J Thorac Cardiovasc Surg 1996;112:1651-60) 
A Popular modification of potassium cardioplegic solutions has been the addition of glutamate and 
aspartate. Although improved myocardial perfor- 
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mance after ischemia was found in rats, a-3 rabbits, 4' 5 
dogs, 6'7 cats, 8 pigs, 9 and human beings, l°' l l  the 
mechanism remains uncertain. Because these com- 
pounds are transaminated to oxaloacetate and ~-ke- 
toglutarate, both citric acid cycle intermediates, 
maintenance of high-energy phosphates has been 
postulated owing to metabolism of these amino 
acids. 12 For example, high concentrations of ~-ke- 
toglutarate may drive production of high-energy 
phosphates by substrate l vel phosphorylation in the 
succinate thiokinase reaction. 13 Sanborn and associ- 
ates 12 emphasized that the overall stoichiometry of 
metabolism of both glutamate and aspartate to 
succinate would allow the redox state to remain 
constant if anaerobic glycolysis continued. Other 
investigators have suggested that the effects of glu- 
tamate may be indirect and mediated by a shift in 
substrate utilization away from free fatty acids. 14 
These hypotheses require that carbon skeletons 
from aspartate or glutamate nter the citric acid 
cycle or that the sources of acetyl coenzyme A 
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Table I. Composition of mixed fatty acids used in 
perfusates compared with those found in rat 
triglyceride stores 
Perfusate Triglycerides s° 
Fatty ac id  Structure (%) (%) 
Pentadecanoic 15:0 2.9 < 2 
Palmitic 16:0 20.2 23 
Palmitoleic 16:1 6.1 4.7 
Hexadecadienoic 16:2 8.8 < 2 
Hexadecatrienoic 16:3 7.1 < 2 
Stearic 18:0 1.8 5.7 
Oleic 18:1 12.1 35.0 
Linoleic 18:2 27.6 24.7 
Linolenic 18:3 13.4 < 2 
Total 100.0 93.1 
The relative concentrations f fatty acids upplied by the manufacturer 
(perfusate) is compared with literature values for fatty acids in rat 
triglycerides. 
(acetyl CoA) be altered. However, these pathways 
supplying the citric acid cycle are seldom quantified. 
An important exception was the observation that 
14C-labeled succinate was generated from both 
[UJ4C]glutamate * and [UJ4C]aspartate.12 In con- 
trast, a recent report 15 found little metabolic effect 
of glutamate plus aspartate. The relevance of either 
study to cardiac surgical conditions is uncertain, 
because neither potassium cardioplegia nor physio- 
logic substrates were used. 
The current study examined the effects of potas- 
sium arrest on selection of substrates for oxidation 
and the effect of aspartate plus glutamate on the 
profile of substrate oxidation in the presence of 
potassium cardioplegia. Somewhat unexpectedly, 
potassium cardioplegia shifted the sources of acetyl 
CoA, but supplementation with glutamate and as- 
partate had little further effect. 
Methods 
Materials. Sodium [3J3C]L-lactate, sodium [3-13C]py- 
ruvate, and [UJ3C]L-glutamic acid were purchased from 
Cambridge Isotopes Inc., Woburn, Massachusetts. [1,3- 
13C]Acetoacetate (prepared by alkaline hydrolysis from 
the ethyl ester) and [U-13C]L-aspartate were obtained 
from Isotec Inc., Miamisburg, Ohio. All of these com- 
pounds were enriched to 99%. Unenriched and [UJ3C] 
(99%) mixed free fatty acids were purchased from Martek 
Inc., Columbia, Maryland. The composition of the labeled 
mixed fatty acids used was similar to that of the fatty acids 
found in rat lipid stores (Table I). 
*The expression [U-14C]glutamate refers to a glutamate molecule 
with all carbon atoms uniformly labeled with the isotope, in 
this case I4C. 
Experimental animals. Male Sprague-Dawley rats 
(three groups of eight each) weighing 250 to 350 gm were 
given food and water ad libitum. All animals were cared 
for in compliance with the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources (National Academy of Sciences) 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Heart perfusions. Rats were anesthetized with chloral 
hydrate (4%, 1 ml/100 gm, intraperitoneally), and heparin 
(1000 U/ml, 0.1 ml/100 gin) was administered via the 
femoral vein. Both superior venae cavae were ligated and 
the heart was excised and perfused retrogradely via the 
aorta at 37 ° C and at a pressure of 100 cm HaO (Lange- 
ndorff preparation). The inferior vena cava was ligated 
and coronary sinus effluent was collected from the pulmo- 
nary artery for determinations of coronary flow and 
myocardial oxygen consumption. 
Left ventricular function was continuously monitored 
by a pressure transducer connected to a fluid-filled latex 
balloon inserted into the left ventricle across the mitral 
valve; end-diastolic pressure was 5 to 12 mm Hg. During 
stabilization hearts were paced at 300 beats/min by way of 
the right atrium if the intrinsic rate fell below this value. 
Myocardial oxygen consumption was calculated from the 
partial oxygen pressures in the inflow and outflow perfu- 
sates and the coronary flow rate. The solubility of oxygen 
was taken to be 3.1 × 10 -5 ml/100 ml/mm Hg, and the 
conversion from volume to moles of oxygen was 22.4 
ml/mmol oxygen (at 273 ° K), multiplied by (310°/273 ° K) 
to convert o the experimental temperature of 37 ° C. 
Perfusate composition. Throughout all phases of all 
experiments (except as noted below) the composition of 
the perfusate was as follows (in millimoles per liter): 118 
NaC1, 4.7 KC1, 1.2 MgSO4, 1.2 NaHaPO4, 25 NaHC03, 1.2 
CaC12, 5.5 glucose, 1.2 lactate, 0.12 pyruvate, 0.17 aceto- 
acetate, 0.35 mixed fatty acids (see Table I), and bovine 
serum albumin, 7.5 gm/L. These are the substrate concen- 
trations present in the serum of a fed, rested rat. 16 The 
"unlabeled" perfusate contained these substrates but 
without 13C enrichment. The "labeled" perfusate con- 
tained these substrates at the same concentration but with 
the 13C enrichment patterns described earlier. In all 
modifications of the perfusion medium (addition of po- 
tassium chloride with or without addition of aspartate and 
glutamate), the sodium chloride concentration was re- 
duced to maintain constant perfusate osmolarity through- 
out all experiments. The perfusate was equilibrated with 
95% oxygen and 5% carbon dioxide with a thin-film 
oxygenator. The perfusate was not recirculated. 
Experimental protocols. After a 20-minute stabiliza- 
tion period with unlabeled perfusate, hearts were ran- 
domly assigned to one of three groups. Controls (group 1) 
were switched to the labeled medium, perfusion was 
continued for 30 minutes, and the heart was freeze- 
clamped. The potassium cardioplegia group (group 2) was 
switched to the labeled perfusate with the potassium 
chloride concentration i creased to 20 mmol/L (and the 
sodium chloride concentration correspondingly de- 
creased). Pacing was discontinued immediately on switch- 
ing to the arrest medium. Perfusion was continued for 30 
minutes, and the heart was freeze-clamped. The gluta- 
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Fig. 1. Proton decoupled 13C-NMR spectrum of an extract from a control heart. PPM, Parts per million. 
mate plus aspartate group (group 3) was switched to the 
labeled perfusate with the following modifications: potas- 
sium chloride, 20 mmol/L; unlabeled aspartate, 13 
mmol/L; unlabeled glutamate, 13 mmol/L. The concentra- 
tions of aspartate and glutamate were taken from the 
reports of Rosenkranz, 6 Allen, w and their associates. 
Hearts were perfused for 30 minutes and freeze-clamped. 
At the end of each experiment, nonventricular tissue was 
rapidly trimmed and hearts were freeze-clamped in alu- 
minum tongs and stored in liquid nitrogen. 
So that metabolism of exogenous glutamate and aspar- 
tate in the citric acid cycle could be tracked directly, 
additional perfusions were done according to the protocol 
for group 3 for the final 30 minutes with [U-13C]glutamate 
(13 mmol/L) as the only enriched substrate (the perfusate 
including aspartate was otherwise not enriched). In addi- 
tional hearts, the identical protocol was followed with 
[U-13C]aspartate (13 mmol/L) as the only labeled compo- 
nent. In these experiments he 13C label originated in either 
glutamate or aspartate, but not both. Because the remainder 
of the experimental conditions were identical to those in 
group 3, the detection of 13C enrichment in intermediates or
products of the citric acid cycle would confirm entry of either 
glutamate or aspartate into the cycle. 
Tissue extraction and 13C-nuclear magnet ic  resonance 
spectroscopy. Frozen hearts were extracted with cold 4% 
perchloric acid (1 gm tissue per 4 ml perchloric acid) and 
centrifuged. The supernatant was neutralized with potas- 
sium hydroxide, centrifuged, and lyophilized. After the 
extract was dissolved in 0.5 ml of deuterium oxide, proton- 
decoupled 13C-nuclear magnetic resonance (NMR) spec- 
tra were obtained in a 5 mm tube at 100.3 MHz on a 9.4 
T Bruker Omega spectrometer (Bruker Instruments, Inc., 
Billerica, Mass.). Sixteen thousand ata points over 22 to 
26 KHz were acquired with a 3-second delay between 
45-degree carbon pulses. Spectra were zero-filled to 
32,000 points before Fourier transformation. Relative 
multiplet areas in the glutamate carbon resonances were 
determined with the use of commercial software (NMR-1, 
Tripos Associates, St. Louis, Mo.). 
Metabol ic  analysis.  With the substrates described ear- 
lier, the acetyl group of acetyl CoA will be labeled in four 
possible patterns: enriched in carbon 1 (derived only from 
acetoacetate), enriched in carbon 2 (derived only from 
pyruvate or lactate in the perfusate), enriched in both 
carbons 1 and 2 (derived only from fatty acids in the 
perfusate), or unenriched (derived from glycogen, tissue 
triglycerides, or glucose in the perfusate). Each of these 
possible labeling patterns is reflected in the enrichment 
pattern of the 4 and 5 carbons of glutamate, which are 
easily distinguished in the 13C-NMR spectrum (see Figs. 1 
and 2). The multiplets from carbons 4 and 5 plus the ratio 
of areas in carbons 4 and 3 were used to calculate the 
fraction of acetyl CoA derived from each substrate: 
Fraction from fatty acids = (C4/C3) • C4Q 
Fraction from lactate or pyruvate = (C4/C3) • C4D34 
Fraction from acetoacetate = (C4/C3) • C4Q. (C5S/C5D) 
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Fig. 2. Nonsteady-state analysis of glutamate C5 and C4. Proton-decoupled t3C-NMR spectra of the C4 
and C5 carbons of glutamate are depicted in the lower panels. These spectra may be resolved into multiplets 
corresponding tothe labeling patterns that may arise in the glutamate molecule. The relative areas of each 
multiplet correspond to the relative utilization of its corresponding substrate source. PPM, Parts per 
million. 
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where C4/C3 is the ratio of resonance areas for carbons 4 
and 3 of glutamate. The multiplets (C4Q, C4D34, and 
C5D) occur when a single resonance is split as a conse- 
quence of carbon-carbon coupling between adjacent I3C 
nuclei, designated J. C4D34 is the area of the doublet 
resulting from enrichment in both carbons 3 and 4; C4Q is 
the area of the quartet resulting from enrichment in 
carbons 3, 4, and 5, and C5D is the area of the doublet 
resulting from enrichment in carbons 4 and 5 (definitions 
from Malloy, Sherry, and Jeffrey17; equations derived 
from Malloy and associateslS). For example, if C4/C3 = 
1.13 and C4Q = 0.51, then the fraction of acetyl CoA 
derived from fatty acids is 1.13 • 0.51 = 0.58. The fraction 
from unlabeled sources (triglycerides, glycogen, or glu- 
cose) was determined by difference from 1. The addition 
of glutamate (13 mmol/L) in group 3 raised the possibility 
that I3C present in natural abundance (1.1%) may be 
detected. However, the other multiplets (C4D34, C4D45, 
and C4Q) cannot be the result of natural abundance 13C. 
Because C4D34/C4Q = C4S/C4D45, TM the area of the 
singlet resulting from natural abundance 13C in perfusate 
glutamate can be determined. This correction was mini- 
mal, and both the observed and the corrected ata are 
reported (Table II). All metabolic analyses were per- 
formed with the corrected ata, but this had little effect on 
the metabolic results. The multiplets from all five gluta- 
mate carbons were also analyzed for control hearts by 
means of the steady-state analysis. 17 
Statistical analysis. Results are presented as mean -+ 
standard deviation and were compared by means of 
one-way analysis of variance (SAS, Inc., Cary, N.C.). 
Results 
Myocardial function and oxygen consumption. 
Hearts  from the control  group remained stable 
throughout he 50-minute perfusion period; rate- 
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Table II. Multiplet areas in the 13C-NMR spectra 
Glutamate + 
Glutamate carbon Multiplet Potassium aspartate + 
resonances or relative Control arrest potassium arrest Corrected 
(chemical shift) area (group 1) (group 2) (group 3) (group 3) 
Carbon 1 S 0.65 -+ 0.02 0.70 _+ 0.06 0.63 _+ 0.12 0.61 + 0.14 
(175.2 ppm) D 0.35 _+ 0.02 0.30 _+ 0.06 0.37 +- 0.12 0.39 _+ 0.14 
Carbon 2 S 0.13 _+ 0.02 0.51 _+ 0.11 0.56 -+ 0.15 0.52 _+ 0.16 
(55.2 ppm) D23 0.17 -+ 0.01 0.09 + 0.04 0.07 _+ 0.02 0.08 _+ 0.03 
D12 0.27 _+ 0.02 0.30 _+ 0.08 0.30 _+ 0.09 0.31 + 0.10 
Q 0.42 _+ 0.04 0.11 + 0.15 0.08 -- 0.07 0.08 _+ 0.08 
Carbon 3 S 0.13 _+ 0.04 0.64 _+ 0.08 0.61 _+ 0.19 0.58 -+ 0.21 
(27.6 ppm) D 0.45 _+ 0.02 0.33 -+ 0.06 0.32 + 0.11 0.34 -- 0.12 
T 0.42 _+ 0.05 0.03 _+ 0.04 0.07 _+ 0.09 0.08 + 0.10 
Carbon 4 S 0.06 _+ 0.02 0.12 _+ 0.03 0.22 _+ 0.15 0.17 _+ 0.17 
(34.2 ppm) D34 0.08 -+ 0.03 0.03 _+ 0.03 0.03 _+ 0.02 0.03 _+ 0.02 
D45 0.35 _+ 0.03 0.65 _+ 0.04 0.56 -+ 0.07 0.60 _+ 0.09 
Q 0.51 _+ 0.03 0.20 _+ 0.05 0.19 + 0.11 0.21 _+ 0.11 
Carbon 5 S 0.31 _+ 0.03 0.74 _+ 0.06 0.67 -+ 0.16 0.64 _+ 0.17 
(181.6 ppm) D 0.69 -+ 0.03 0.26 + 0.06 0.33 +_ 0.16 0.36 _+ 0.17 
(Area carbon 4)/ C4C3 1.13 + 0.05 1.09 _+ 0.12 1.22 _+ 0.26 1.25 _+ 0.24 
(Area carbon 3) 
Each letter efers to the area of that multiplet relative to the total resonance area of that carbon: S, singlet; D, doublet resulting from J coupling with a single 
adjacent carbon atom, as noted; Q, quartet (doublet of doublets)i T, triplet resulting from glutamate labeled in C2, C3, and C4. The area of the C4 relative 
to the C3 resonance is C4C3 (n = 8 in each group). 
pressure product changed less than 10% during 
perfusion with 13C-labeled compounds. Oxygen con- 
sumption in the control group was 53.3 +_ 10.0 
txmol/gm dry weight per minute. Hearts exposed to 
a 20 mmol/L concentration of potassium (groups 2 
and 3) ceased beating within 15 seconds of exposure 
to the arresting medium (separate experiments 
showed complete recovery of mechanical function 
after switching back to a 4.7 mmol/L concentration 
of potassium chloride). At the end of 30 minutes of 
potassium arrest, oxygen consumption in group 2 
was 21.6 _+ 6.7 /xmol/gm dry weight per minute, 
significantly less than in the control group (p < 
0.05). Oxygen consumption in hearts exposed to 
glutamate plus aspartate during potassium arrest 
(group 3) was 16.7 +_ 1.7 txmol/gm dry weight per 
minute, not significantly different from values in 
hearts exposed to potassium arrest alone (group 2). 
Together, these results howed that potassium chlo- 
ride arrest produced a significant and substantial 
decrease in oxygen consumption, but that glutamate 
plus aspartate had no significant additional effect on 
oxygen consumption. 
laC-NMR spectra and selection of substrates for 
oxidation. The ~3C-NMR spectra of hearts perfused 
under control conditions (see Fig. 1) were similar to 
those in previous reports ~9 and demonstrated that 
under these conditions all of the ~3C-enriched sub- 
strates, even when present in low concentrations, 
were oxidized in the citric acid cycle. The relative 
intensities of the multiplets of glutamate are sum- 
marized in Table II. Analysis of these multiplets by 
the nonsteady-state m thod showed that fatty acids, 
as expected, contributed the majority of acetyl CoA, 
about 58%, and that acetoacetate contributed most 
of the remaining oxidized carbon, about 24% (Table 
III). The remaining acetyl CoA originated either 
from lactate or pyruvate provided in the perfusate 
(10%) or from unlabeled sources uch as endoge- 
nous triglyceride stores, glycogen, or unlabeled glu- 
cose in the perfusate. These unlabeled sources con- 
tributed only 8% of the total acetyl CoA. The 
sources of acetyl CoA calculated by the steady-state 
analysis were virtually identical to the nonsteady- 
state results: fatty acids, 57% + 4%; acetoacetate, 
26% _+ 3%; lactate or pyruvate, 10% _+ 3%; unla- 
beled sources, 6% +_ 4%. 
Potassium arrest dramatically altered the 13C- 
NMR spectrum of glutamate (Fig. 3 and Table II), 
indicating different sources of acetyl CoA. Fig. 3 
shows a decrease in the doublet detected in the C5 
of glutamate, which indicates a decrease in the 
oxidation of fatty acids relative to acetoacetate. The 
nonsteady-state analysis of the sources of acetyl 
CoA (see Table III) found a significant decrease in 
both fatty acid and lactate contribution to acetyl 
CoA caused by potassium arrest, which was bal- 
anced by a substantial increase in contribution from 
acetoacetate. Thus, although fatty acids are the 
preferred substrate for oxidation in normally per- 
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Table III. Fraction of acetyl CoA derived from available substrates 
Contribution to acetyl Coil (%) 
Lactate or Unlabeled 
Experimental group pymvate Fatty acids Acetoacetate sources 
Contro l  10 _+ 4* 58 -+ 5* 24 _+ 2* 8 + 4 
Potass ium arrest  4 -- 3 23 + 5 62 +_ 6* 11 _+ 6 
Potass ium arrest  + g lu tamate  + aspar tate  4 _+ 2 31 _+ 17 45 _+ 12" 19 +_ 18 
The contribution of exogenous substrates to acetyl CoA was determined from the data in Table II (n = 8, each group). The contribution f each substrate 
to acetyl CoA under each experimental condition was compared by analysis of variance. 
*The contribution of a substrate to acetyl CoA was different from the other two groups at p < 0.05. 
fused hearts, potassium chloride arrest shifts sub- 
strate preference to acetoacetate. 
The addition of unlabeled glutamate and aspar- 
tate caused little further change in the 13C-NMR 
spectra (Fig. 3 and Table III). The contribution of 
acetoacetate o acetyl CoA was significantly less 
than was the contribution of potassium arrest alone, 
but the magnitude of this effect was modest. 
Metabolism of glutamate and aspartate. Al- 
though glutamate and aspartate did not have a 
dramatic effect on the profile of substrate selection, 
direct metabolism as intermediates of the citric acid 
cycle had not been excluded, because the studies 
described herein determined only the sources of 
acetyl CoA and not the activity of other pathways 
feeding the cycle. Therefore a small number of 
hearts were perfused with the same substrate mix- 
ture as group 3, except hat the site of 13C enrich- 
ment was either [UJ3C]glutamate (13 mmol/L) or 
[UJ3C]aspartate (13 mmol/L). 
Under these conditions, [UJ3C]glutamate sup- 
plied in the perfusate is trapped in the interstitial 
space and therefore included in the freeze- 
clamped tissue, where the 13C label will be de- 
tected by NMR. This experiment cannot distin- 
guish extracellular glutamate from intracellular 
glutamate that has not been metabolized, because 
the 13C labeling patterns are identical. However, 
once [U-13C]glutamate enters the citric acid cycle 
(via oz-ketoglutarate), it will be metabolized to 
[U-13C]oxaloacetate. Condensation with unla- 
beled acetyl CoA (the available oxidizable sub- 
strates were not all enriched in this experiment) 
produces [1,2,3-13C]citrate and, subsequently, 
[1,2,3J3C]glutamate. This labeling pattern is eas- 
ily distinguished from [UJ3C]glutamate, because 
enrichment in carbon 3 is detected as a doublet 
resulting from J2,3 (rather than the apparent 
triplet that would be produced as a result of J2,3 
and J3,4 from [UJ3C]glutamate in the perfusate). 
Metabolism of [U-13C]glutamate was not detected 
(data not shown). 
There are two possible pathways for aspartate 
metabolism after transamination to oxaloacetate: 
(1) condensation with unlabeled acetyl CoA to form 
citrate or (2) decarboxylation to pyruvate. So that 
aspartate metabolism could be monitored irectly, 
additional perfusions were done with [U-13C]aspar - 
tate (13 mmol/L) as the only labeled compound. If
aspartate enters the cycle via transamination, 
[UJ3C]oxaloacetate will be produced, which will 
combine with unlabeled acetyl CoA and subse- 
quently form a-ketoglutarate enriched in carbons 1, 
2, and 3. The corresponding glutamate ([1,2,3- 
13C]glutamate) will show a doublet resulting from 
13C-13C spin-spin coupling in carbon 3 at about 27.6 
ppm. A small doublet was indeed detected, showing 
that a small amount of glutamate was derived from 
the pathway [UJ3C]aspartate ~ [UJ3C]oxaloac- 
etate ~ [1,2,3J3C]citrate ~ ~ [1,2,3-13C]c~-keto - 
glutarate (Fig. 4, A). The singlet is primarily caused 
by I3C present in glutamate at natural abundance 
(1.1%). Therefore much less than 1% of ~-ketoglu- 
tarate was derived from the aspartate provided in 
the perfusate. 
The alternative pathway for aspartate metabo- 
lism, [UJ3C]aspartate ~ [UJ3C]oxaloacetate 
[U-13C]pyruvate --~ [1,2-13C]acetyl CoA --~ [4,5- 
~3C]citrate, yields [4,5-13C]glutamate (see Fig. 4, B). 
In this case, J4,5 (but not J3,4) will be detected in the 
carbon 4 resonance of glutamate at 34.2 ppm. This 
multiplet (the doublet in C4 resulting from J4,5) was 
detected, although the resonances were again small 
compared with the singlet. Because the singlet at 
34.2 ppm is derived primarily from 13C present at 
natural abundance (1.1%), these observations indi- 
cate that aspartate indeed is oxidized via acetyl CoA 
in the citric acid cycle, but that it is quantitatively 
negligible: less than 1% of acetyl CoA was derived 
from aspartate. 
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Fig. 3. Representative glutamate C4 and C5 spectra from hearts from each group. Simple inspection indicates 
that peaks labeled F and L (for fatty acids and lactate, respectively) are reduced in bothcardioplegia groups, 
whereas those labeled K (for ketones) are increased. GA, Glutamate and aspartate; ppm, parts per million. 
Anaplerosis. The entry of carbon skeletons into 
the citric acid cycle via pathways uch as pyruvate 
carboxylation or net flow of an amino acid into the 
cycle through a transamination reaction has been 
termed anaplerosis. The ratio of flux through these 
combined pathways relative to citric acid cycle flux has 
been given the variable name y. Analysis 17 of the data 
in Table II found a y of 11% + 3% under control 
conditions, and a significant fraction of the carbon 
skeletons (about 0.48 _+ 0.05) entering the citric acid 
cycle through anaplerosis was derived from the pyru- 
vate plus lactate pool in the perfusate. Because arlier 
studies20, 21 have shown that the assumption of steady 
state may not be reliable after 30 minutes during 
potassium chloride arrest, the steady-state analysis was 
not applied in those groups. 
Discussion 
Selection of substrates for oxidation: effects of 
cardioplegia nd amino acids. Unlike most studies 
of isolated hearts, five oxidizable substrates that are 
normally present in blood were provided in this 
experiment. Under control conditions, the sources 
of acetyl CoA were similar to those reported re- 
cently by Jeffrey and colleagues) 9 The current study 
confirms the relatively large contribution of aceto- 
acetate ven in the presence of long-chain fatty acids 
under control conditions. Potassium chloride arrest 
inhibited oxidation of both fatty acids and the 
lactate plus pyruvate pool, and acetoacetate b came 
the dominant source of acetyl CoA. The uptake of 
fatty acids is a carrier-mediated process, 22 and the 
transmembrane transport of fatty acids is inhibited 
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Fig. 4. Pathways for [U-13C]aspartate entry into the citric acid cycle. A, If [UJ3C]aspartate (filled circles) 
is metabolized to oxaloacetate and citrate, then 13CJ3C coupling must be detected as a doublet in the 
glutamate C3 resonance, shown in the lower spectrum. B, If [U-13C]aspartate forms oxaloacetate and 
subsequently generates pyruvate, this labeled pyruvate could form labeled acetyl CoA and produce 
glutamate enriched in carbons 4 and 5. This pattern will be detected as a doublet in the glutamate C4 
caused by 13C-13C coupling between carbons 4 and 5. PPM,, Parts per million. 
by depolarization i the isolated liver. 23 High con- 
centrations of potassium also stimulate myocardial 
pyruvate dehydrogenase kinase and thereby reduce 
pyruvate dehydrogenase activity. 24 Because oxida- 
tion of both lactate and pyruvate in the citric acid 
cycle requires flux through this enzyme complex, its 
inhibition may reduce carbohydrate contribution to 
acetyl CoA. Together, these effects of potassium 
chloride should inhibit oxidation of both carbohy- 
drates and long-chain fatty acids, which would be 
reflected as an increase in the contribution of the 
only remaining substrate, acetoacetate, to acetyl 
CoA. 
The addition of glutamate and aspartate had little 
further effect on substrate utilization patterns. Ear- 
lier in vivo studies TM found that the profile of sub- 
strate selection is sensitive to glutamate, but this 
effect was likely mediated by systemic hanges in 
substrate and insulin concentrations. 
Minimal entry of labeled amino acids into the 
citric acid cycle. Studies performed with 13C-la- 
beled glutamate failed to demonstrate entry of this 
amino acid into the cycle by any route. This conclu- 
sion contrasts with the report by Sanborn and 
associates, 12 who detected 14C-labeled carbon diox- 
ide release and 14C-enriched succinate in myocar- 
dium exposed to 14C-enriched glutamate. However, 
as noted by these authors, the rate of glutamate 
metabolism to succinate or other relative flux mea- 
surements could not be determined. The current 
study differed in several respects, including species, 
potassium chloride arrest, and method of detecting 
metabolism of enriched glutamate. Hence, although 
the studies cannot be directly compared, one con- 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 6 
Reed et al. 1659 
sistent interpretation is that the more sensitive 
technique (14C tracer analysis) detected glutamate 
metabolism, but that the quantitative significance is
minimal relative to the activity of other pathways 
feeding the citric acid cycle. 
The early documentation f 14C-labeled aspartate 
metabolism in the rabbit myocardium 12was later 
confirmed by studies with [4J1C]aspartate detected 
by positron computed tomographyY The current 
study extended these observations by showing me- 
tabolism of aspartate via both anaplerosis (aspartate 
oxaloacetate ~ citrate) and net oxidation (aspar- 
tate -~ --~ acetyl CoA --+ citrate). However, the rate 
of aspartate metabolism through either pathway is 
negligible (probably less than 1% of total citric acid 
cycle flux). Together, these reports illustrate the 
complementariness of carbon radioisotope methods 
and 13C-NMR. Radiotracer techniques detected 
amino acid metabolism with high sensitivity, 
whereas the 13C-NMR isotopomer analysis provided 
simultaneous measurements of other metabolic 
pathways. 
Clinical relevance. This study did not find sub- 
stantial effects of these amino acids on citric acid 
cycle function. These observations are consistent 
with those of Galifianes, Chambers, and Hearse, 26 
who found that the addition of aspartate to a 
long-term cardioplegic storage solution had no ef- 
fect after controlling for sodium concentration, and 
those of Crooke and associates, 27 who found that 
the addition of amino acids offered no further 
benefit in their cardioplegic solutions. Although 
these amino acids have been studied as additives to 
cardioplegic solutions in clinical trials, some 28 but 
not all 29 reports favor their use. 
Study limitations. This model differed from some 
earlier studies because the heart was perfused in the 
absence of red cells (albumin was present). How- 
ever, much of the experimental justification for 
amino acid supplementation is based on the crystal- 
loid-perfused heart, and at least one report indicates 
that glutamate is effective only in crystalloid-per- 
fused myocardium. 9 The concentrations of sub- 
strates were based on those found in the fed, rested 
animal; the concentration during extracorporeal cir- 
culation may differ significantly. If the effects of 
amino acids are dependent on available substrate or 
an interaction among available substrate, ischemia 
and potassium ion concentration, then a significant 
effect may have been missed. Finally, our study was 
performed in rats. A beneficial effect limited to 
some species is possible, but other studies have 
reported functional benefits in many species includ- 
ing rats. 
The technical assistance of Robert Y. Chao and Kim- 
berley Ross is appreciated. 
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